• Advances in the Understanding of Etiology (I)
• 30 min
  1. Infection and autoimmunity: a two-way relationship

  • Dr. Ricard Cervera
• 35 min
  2. Autoimmunity and atherosclerosis

  • Prof. Johan Frostegard
• 47 min
  3. Endothelium and autoimmunity

  • Prof. Pier Luigi Meroni
• Advances in the Understanding of Etiology (II)
• 22 min
  4. Prolactin has a pathogenic role in systemic lupus erythematosus

  • Prof. Luis Jara-Quezada
• 44 min
  5. Sjögren's syndrome: current knowledge and future prospects

  • Prof. Athanasios G. Tzioufas
• 51 min
  6. Genetic and environmental triggers of autoimmune thyroid diseases

  • Prof. Yaron Tomer
• Advances in Pathogenesis and Clinical Manifestation
• 38 min
  7. The catastrophic antiphospholipid syndrome and the microangiopathic antiphospholipid syndrome

  • Prof. Ronald Asherson
• 20 min
  8. Pathogenic mechanisms of autoantibodies: circulating and local antibodies that form immune complexes

  • Dr. Luís Eduardo Coelho Andrade
• 34 min
  9. Pathogenic mechanisms of autoantibodies: antibodies to intracellular and membrane-bound antigens

  • Dr. Luís Eduardo Coelho Andrade
• 43 min
  10. What causes primary biliary cholangitis?

  • Dr. M. Eric Gershwin
• 30 min
  11. Capillaroscopy in autoimmune rheumatic diseases

  • Prof. Maurizio Cutolo
• Advances in Diagnostic Methodologies (I)
• 26 min
  12. The past, present & future of ANA testing: history and challenges of ANA

  • Prof. Marvin J. Fritzler
• 33 min
  13. The past, present & future of ANA testing: changing bandwidth and future of ANA

  • Prof. Marvin J. Fritzler
• 36 min
  14. Diagnostic methods in autoimmunity

  • Mr. Steven Binder
• 24 min
  15. Systemic lupus erythematosus: novel aspects of pathogenesis and treatment 1

  • Prof. Chaim Putterman
  • Dr. Noa Schwartz
• 28 min
  16. Systemic lupus erythematosus: novel aspects of pathogenesis and treatment 2

  • Prof. Chaim Putterman
  • Dr. Noa Schwartz
• 48 min
  17. Novel aspects of systemic sclerosis

  • Prof. Gabriele Valentini
• Advances in Diagnostic Methodologies (II)
• 46 min
  18. An update on the multiple faces of celiac disease

  • Prof. Aaron Lerner
• 23 min
  19. Protective autoantibodies

  • Prof. Elias Toubi
• 32 min
  20. CD44 genetic deletion enhances and CD44 antibody targeting attenuates autoimmune inflammation

  • Prof. David Naor
• 44 min
  21. Rheumatic fever: a model of a post-infectious autoimmune disease

  • Prof. Jorge Kalil
• Treatments of autoimmune diseases
• 38 min
  22. Intravenous immunoglobulins: clinical evidence

  • Prof. Shaye Kivity
• Latest Developments in the Field
• 26 min
  23. Adjuvants and autoimmunity

  • Dr. Eitan Israeli
• 46 min
  24. Antiphospholipid syndrome (APS): from pathogenesis to treatment

  • Prof. Roger Levy
• 24 min
  25. Vitamin D and autoimmunity

  • Dr. Shir Azrielant
• 28 min
  26. Pregnancy in rheumatic diseases

  • Prof. Pier Luigi Meroni
• Archived Lectures *These may not cover the latest advances in the field
• 47 min
  27. Pathogenic mechanisms of autoantibodies

  • Prof. Cees Kallenberg
• 41 min
  28. B lymphocytes on the frontline of autoimmunity

  • Prof. Pierre Youinou
• 42 min
  29. Apoptotic cell clearance deficiency

  • Prof. Martin Herrmann
• 34 min
  30. Auto-antibodies as predictors of autoimmune disease

  • Dr. Nicola Bizzaro
• 46 min
  31. Innate immunity and natural autoantibodies

  • Prof. Luc Mouthon
• 45 min
  32. Accelerated atherosclerosis in autoimmune rheumatic disease

  • Dr. Andrea Doria
• 47 min
  33. Pregnancy in autoimmune rheumatic diseases

  • Prof. Angela Tincani
• 42 min
  34. Pulmonary hypertension in the connective tissue disease pathogenesis, clinical features and therapeutic options in 2006

  • Prof. Ronald Asherson
• 39 min
  35. Use of algorithms for high quality diagnostics and handling of patients with autoimmune rheumatic diseases

  • Dr. Allan Wiik
• 24 min
  36. Immunologic mechanisms in systemic lupus erythematosus

  • Prof. Kok-Yong Fong
• 23 min
  37. Osteoimmunology

  • Prof. João Eurico Fonseca
  • Ms. Joana Caetano-Lopes
• 43 min
  38. ANCA-associated systemic vasculitides

  • Prof. Loic Guillevin
• 23 min
  39. The common origin for diverse autoimmune diseases

  • Prof. Juan-Manuel Anaya
• 76 min
  40. Anti-cytokine therapy in rheumatoid arthritis

  • Prof. Piercarlo Sarzi-Puttini
• 40 min
  41. Sjogren's syndrome: autoimmune epithelitis

  • Prof. Haralampos Moutsopoulos
• 31 min
  42. Vitamin D and autoimmunity

  • Dr. Howard Amital
• 25 min
  43. Intravenous immunoglobulins: myth and reality

  • Prof. Zera Tellier

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Definitions and classification
3. Fibrinoid necrosis of the artery
4. Chapel hill nomenclature
5. PAN: 1990 ACR criteria
6. PAN and MPA
7. Vasculitides and nephrons
8. Capilaritis in lungs
9. Epidemiology
10. Microscopic polyangiitis
11. Wegener's granulomatosis (1)
12. Churg-Strauss syndrome
13. Seine-St-Denis survey
14. Prevalence
15. Incidence of vasculitides in three European areas
16. Why vasculitis is more frequently observed today?
17. Time trends: Wegnere's granulomatosis
18. Age specific incidence of vasculitis
19. Pathogenesis
20. ANCA in systemic vasculitis
21. Role of PR3 in pathogenesis
22. ANCA induce glomerulonephritis in mice
23. Stage A - resting PR3
24. Stage B - stimulation by primary antigen
25. Stage C - adhesion molecules expression
26. Stage D - binding
27. Stage E - activation
28. Stage F - destruction
29. Injury
30. Pathogenesis - other mechanisms
31. Treatment
32. EUVAS and FVSG
33. Treatment of systemic vasculitis (1)
34. Assessment
35. Assessment in necrotizing vasculitis
36. Five factor score
37. Prognostic scores in PAN, MPA and CSS
38. BVAS (different versions)
39. Survival curve: according to CYC dose
40. Survival curve: according to CYC and FFS
41. Survival curve: according to CYC and BVAS
42. Optimization of conventional treatments
43. Oral cyclophosphamide
44. Recommendations for pulse cyclophosphamide
45. Pulse cyclophosphamide
46. Oral vs. pulse CYC in Wegener's
47. Wegener's granulomatosis: 50 patients (1)
48. Wegener's granulomatosis: 50 patients (2)
49. ANCA+ vasculitides
50. CYCLOPS - study design
51. CYCLOPS - epidemiology
52. Outcomes
53. Disease free survival
54. Deaths
55. Poor prognosis and steroids treatment
56. Treatment: PAN, MPA and CSS (1)
57. Treatment of CSS: FFS = 0
58. Treatment of patients with poor prognosis
59. Treatment: PAN, MPA and CSS (2)
60. PAN/MPA patients treated with 6/12 CY pulse CS
61. Treatment of systemic vasculitis (2)
62. CYCAZAREM protocol
63. CYCAZAREM protocol: results (1)
64. CYCAZAREM protocol: results (2)
65. CYCAZAREM protocol: results (3)
66. NORAM protocol
67. NORAM protocol: results
68. The WEGENT study
69. The desighn of WEGENT study
70. WEGENT study: no. of patients
71. WEGENT study: statistics
72. Relapse-free survival curves in the WEGENT study
73. Event-free survival curves in the WEGENT study
74. Wegener's vs. MPA in the WEGENT study
75. Plasma exchanges - MEPEX protocol
76. Plasma exchanges (MEPEX study): survival
77. Plasma exchanges (MEPEX study): renal recovery
78. New drugs and new treatments
79. Mycophenolate in vasculitis
80. IMPROVE strudy
81. Treatment of vasculitides with etanercept
82. Biologics in systemic vasculitis
83. Monoclonal anti-CD20 (rituximab)
84. Rituximab in Wegener's
85. RAVE study
86. How to treat relapses and refractory patients?
87. Relapses of systemic vasculitis (1)
88. Relapses in Wegener's granulomatosis
89. Wegener's prognostic factors (1)
90. Wegener's prognostic factors (2)
91. IGANCA protocol (1)
92. IGANCA protocol (2)
93. Methotrexate in Wegener's (1)
94. Methotrexate in Wegener's (2)
95. Other treatment for relapses
96. Anti-TNF
97. Infliximab in necrotizing vasculitides
98. Treatment of vasculitides with infliximab (1)
99. Treatment of vasculitides with infliximab (2)
100. Relapses of systemic vasculitis (2)
101. Prevention of relapses
102. Specific treatments for specific problems
103. Treatment of systemic vasculitis (3)
104. PAN and CSS after 65 (1)
105. PAN and CSS after 65 (2)
106. Wegner's granulomatosis (2)
107. Example from a patient (1)
108. Example from a patient (2)
109. Conclusion (1)
110. Conclusion (2)
111. Learn more about vasculitides

Topics Covered

• Definitions and classification
• PAN- versus ANCA-associated vasculitides
• Epidemiology
• Pathogenesis
• Treatment
• Optimization of conventional treatments
• Assessment
• New drugs and strategies
• Relapses
• Specific treatments for specific problems

Links

Series:

• Autoimmunity

Categories:

• Clinical Practice
• Immunology

Therapeutic Areas:

• Immunology & Inflammation

Talk Citation

Publication History

• Published on October 1, 2007
• Archived on October 25, 2018

Financial Disclosures

• Prof. Loic Guillevin has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.